About Arecor
Arecor Ltd. develops stabilization technology solutions for pharmaceutical and biotech companies developing recombinant proteins and vaccines for application in drugs, medical devices, or diagnostics. It offers Arestat, a stabilization technology that enables the formulation of labile proteins and vaccines as stable aqueous or dry preparations at high concentrations or in the presence of ionizing radiation. The company’s Arestat comprises various aspects of the protein stabilization technologies, such as Arestat-T for the stabilization of biologicals at nominal or very high concentrations during storage at refrigerated, ambient, or elevated temperatures; and Arestat-R for the stabilization of biologicals exposed to ionizing radiation, as well as for the protection of biologicals from radiation damage. It offers its Arestat-T and Arestat-R to improve the stability of recombinant proteins, vaccines, and macromolecules. The company also provides a set of formulation tools to address the pathways of degradation that lead to the loss of structural integrity and biological activity. It offers its products for labile biologics, replacing powders with stable aqueous presentations, higher concentrations of biopharmaceuticals, heat stability, depot delivery, drug /device combinations, and diagnostics applications.
Arecor Description
Arecor Ltd. develops stabilization technology solutions for pharmaceutical and biotech companies developing recombinant proteins and vaccines for application in drugs, medical devices, or diagnostics. It offers Arestat, a stabilization technology that enables the formulation of labile proteins and vaccines as stable aqueous or dry preparations at high concentrations or in the presence of ionizing radiation. The company’s Arestat comprises various aspects of the protein stabilization technologies, such as Arestat-T for the stabilization of biologicals at nominal or very high concentrations during storage at refrigerated, ambient, or elevated temperatures; and Arestat-R for the stabilization of biologicals exposed to ionizing radiation, as well as for the protection of biologicals from radiation damage. It offers its Arestat-T and Arestat-R to improve the stability of recombinant proteins, vaccines, and macromolecules. The company also provides a set of formulation tools to address the pathways of degradation that lead to the loss of structural integrity and biological activity. It offers its products for labile biologics, replacing powders with stable aqueous presentations, higher concentrations of biopharmaceuticals, heat stability, depot delivery, drug /device combinations, and diagnostics applications.